REZOLUTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.80% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.90%.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-09-30 was 1.90%.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.46%, a 23.56% decline year-over-year.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.91%.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2026 was 3.80%, a 9.52% decline from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.20%, a 0.00% change from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 13.51% increase from fiscal 2023.
- REZOLUTE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.70%, a 19.35% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.80% 10-K · filed 2026-09-24 | |||
| 2026-03-31 | 3.80% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 3.80% 10-Q · filed 2026-02-12 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.20% 10-K · filed 2026-09-24 | |||
| 2024-06-30 | 4.20% 10-K · filed 2025-09-17 | |||
| 2023-06-30 | 3.70% 10-K · filed 2024-09-19 | |||
| 2022-06-30 | 3.10% 10-K · filed 2023-09-14 | |||
| 2021-06-30 | 0.90% 10-K · filed 2022-09-15 | |||
| 2020-03-31 | 1.90% 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | 1.90% 10-Q · filed 2020-02-12 | |||
| 2019-09-30 | 1.90% 10-Q · filed 2019-11-14 | |||
| 2016-09-30 | 1.46% 10-Q · filed 2016-11-14 | |||
| 2016-03-31 | 1.91% 10-Q · filed 2016-05-16 | |||
| 2015-12-31 | 1.91% 10-Q · filed 2016-02-16 | |||
| 2015-09-30 | 1.91% 10-Q · filed 2015-11-16 | |||
| 2013-03-31 | 0.88% 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |